Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis

IF 2 Q3 NEUROSCIENCES IBRO Neuroscience Reports Pub Date : 2024-11-08 DOI:10.1016/j.ibneur.2024.11.004

Sowmiya S , Dhivya L.S. , Praveen Rajendran , Harikrishnan N , Ankul Singh S

{"title":"Exploring the potential of probiotics in Alzheimer's disease and gut dysbiosis","authors":"Sowmiya S , Dhivya L.S. , Praveen Rajendran , Harikrishnan N , Ankul Singh S","doi":"10.1016/j.ibneur.2024.11.004","DOIUrl":null,"url":null,"abstract":"<div><div>Alzheimer's disease is a fatal neurodegenerative disorder that causes memory loss and cognitive decline in older people. There is increasing evidence suggesting that gut microbiota alteration is a cause of Alzheimer’s disease pathogenesis. This review explores the link between gut dysbiosis and the development of Alzheimer's disease contributing to neuroinflammation, amyloid β accumulation, and cognitive decline. We examine the recent studies that illustrate the gut-brain axis (GBA) as a bidirectional communication between the gut and brain and how its alteration can influence neurological health. Furthermore, we discuss the potential of probiotic supplementation as a management approach to restore gut microbiota balance, and ultimately improve cognitive function in AD patients. Based on current research findings, this review aims to provide insights into the promising role of probiotics in Alzheimer's disease management and the need for further investigation into microbiota-targeted interventions.</div></div>","PeriodicalId":13195,"journal":{"name":"IBRO Neuroscience Reports","volume":"17 ","pages":"Pages 441-455"},"PeriodicalIF":2.0000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IBRO Neuroscience Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667242124000988","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Alzheimer's disease is a fatal neurodegenerative disorder that causes memory loss and cognitive decline in older people. There is increasing evidence suggesting that gut microbiota alteration is a cause of Alzheimer’s disease pathogenesis. This review explores the link between gut dysbiosis and the development of Alzheimer's disease contributing to neuroinflammation, amyloid β accumulation, and cognitive decline. We examine the recent studies that illustrate the gut-brain axis (GBA) as a bidirectional communication between the gut and brain and how its alteration can influence neurological health. Furthermore, we discuss the potential of probiotic supplementation as a management approach to restore gut microbiota balance, and ultimately improve cognitive function in AD patients. Based on current research findings, this review aims to provide insights into the promising role of probiotics in Alzheimer's disease management and the need for further investigation into microbiota-targeted interventions.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索益生菌在阿尔茨海默病和肠道菌群失调中的潜力

阿尔茨海默病是一种致命的神经退行性疾病，会导致老年人记忆力减退和认知能力下降。越来越多的证据表明，肠道微生物群的改变是阿尔茨海默病发病机制的一个原因。本综述探讨了肠道菌群失调与阿尔茨海默病发病之间的联系，阿尔茨海默病会导致神经炎症、淀粉样蛋白 β 累积和认知能力下降。最近的研究表明，肠道-大脑轴（GBA）是肠道和大脑之间的双向交流，而肠道-大脑轴的改变又会如何影响神经系统的健康。此外，我们还讨论了补充益生菌作为恢复肠道微生物群平衡的管理方法的潜力，并最终改善注意力缺失症患者的认知功能。基于当前的研究成果，本综述旨在深入探讨益生菌在阿尔茨海默病治疗中的前景，以及进一步研究微生物群靶向干预措施的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊